We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Philips Healthcare

Operates in Diagnostic Imaging Systems, Patient Care and Clinical Informatics, Customer Services, and Home Healthcare... read more Featured Products: More products

Download Mobile App




Cardiac Troponin Assay Compared with Existing Tests

By LabMedica International staff writers
Posted on 02 May 2017
Efficient rule-out of acute myocardial infarction (MI) in patients presenting with symptoms of cardiac ischemia facilitates early disposition of the patient to outpatient care, and helps to relieve the increasing crowding of the emergency departments (ED) in most hospitals.

Sensitive cardiac troponin (cTn) assays support such a decision based on results at admission and three hours after admission, according to current guidelines. More...
The time needed for results to become available from the hospital central laboratory often delays the disposition decision for another one or two hours.

An international team of scientists collaborating with those at the University of Uppsala compared a novel point-of-care assay (POC) for cardiac troponin I with a high-sensitivity cardiac troponin I laboratory assay. They enrolled 450 prospectively patients admitted with suspected MI at EDs or coronary care units/chest pain units of seven hospitals in Germany, France, Austria and the Netherlands. Patients eligible for enrolment were adults (age ≥ 18 years) who had presented with symptoms suggestive of MI. Only patients who presented for the first time and less than 12 hours from onset of symptom onset were included.

The novel cTnI POC test, the Minicare cTnI, provides a cTnI result within 10 minutes. The test was compared with two widely used cTnI assays: the Abbott Architect hs-cTnI and the POC Abbott I-Stat cTnI. The concentrations of cTnT in lithium-heparin plasma were measured at the local hospital laboratories using a hs-cTnT assay.

The team observed significant correlations for cTnI concentrations measured on the Minicare cTnI, either as whole blood or plasma, compared with the Architect hs-cTnI and I-Stat cTnI. There was evidence of bias for both comparisons: 0.59 (whole blood) and 0.48 (plasma) for the Architect hs-cTnI and 0.48 (whole blood) and 0.43 (plasma) for the I-Stat cTnI. The 8% discordant results among MI patients between Minicare cTnI and Architect hs-cTnI were almost equally distributed with 3% showing elevated concentrations with Minicare cTnI and 5% showing elevated results with Architect hs-cTnI, but non-elevated results with the other.

The authors concluded that that the novel Minicare cTnI POC assay equals the clinical performance in their patient cohort of a hs-cTnI assay. The Minicare cTnI assay, with a very high negative predictive value, may become suitable for prompt and safe rule-out of MI for patients with symptoms suggestive of MI in the emergency setting using a 0/3 hour sampling protocol. The study was published online on March 25, 2017, in the journal Clinica Chimica Acta.


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Chagas Disease Test
LIAISON Chagas
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.